HIMS Stock Eyes Best Day Ever After Dispute Dissolution

Core Viewpoint - Hims & Hers Health Inc's stock surged over 35% to $21.27 following the resolution of a dispute with Novo Nordisk, allowing patients to switch to competing weight-loss drugs [1] Group 1: Stock Performance - Hims & Hers shares reached a two-year low of $13.73 on February 24, but have now surpassed $20 for the first time since early February, although they remain 33% lower than in 2026 [2] - A significant short squeeze is contributing to the stock's gains, with short interest comprising 39.6% of the stock's available float, indicating it would take shorts nearly four days to cover their positions [2] Group 2: Options Activity - At the International Securities Exchange, Cboe Options Exchange, and NASDAQ OMX PHLX, Hims's 10-day call/put volume ratio of 5.00 is in the top 2% of readings from the past year, suggesting potential bearish bettors are using calls as a hedge [3] - Over 180,000 call options have been traded today, which is five times the average intraday volume and three times the number of puts traded, indicating strong interest in call options [4] - The most popular options include the weekly 3/13 25-strike call and the standard April 25 call, with a Schaeffer's Volatility Scorecard (SVS) of 86 out of 100, indicating higher realized volatility than what options pricing suggests [4]